- Home
- TDTH vs PASG Comparison
TDTH vs PASG Comparison
Compare TDTH & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDTH
- PASG
- Stock Information
- Founded
- TDTH 2014
- PASG 2017
- Country
- TDTH Singapore
- PASG United States
- Employees
- TDTH 23
- PASG N/A
- Industry
- TDTH
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- TDTH
- PASG Health Care
- Exchange
- TDTH NYSE
- PASG Nasdaq
- Market Cap
- TDTH 20.0M
- PASG 20.3M
- IPO Year
- TDTH 2024
- PASG 2020
- Fundamental
- Price
- TDTH $0.46
- PASG $6.55
- Analyst Decision
- TDTH
- PASG Strong Buy
- Analyst Count
- TDTH 0
- PASG 3
- Target Price
- TDTH N/A
- PASG $7.67
- AVG Volume (30 Days)
- TDTH 10.0M
- PASG 515.7K
- Earning Date
- TDTH 07-22-2025
- PASG 08-07-2025
- Dividend Yield
- TDTH N/A
- PASG N/A
- EPS Growth
- TDTH N/A
- PASG N/A
- EPS
- TDTH N/A
- PASG N/A
- Revenue
- TDTH $465,435.00
- PASG N/A
- Revenue This Year
- TDTH N/A
- PASG N/A
- Revenue Next Year
- TDTH N/A
- PASG N/A
- P/E Ratio
- TDTH N/A
- PASG N/A
- Revenue Growth
- TDTH N/A
- PASG N/A
- 52 Week Low
- TDTH $0.17
- PASG $0.26
- 52 Week High
- TDTH $4.74
- PASG $7.63
- Technical
- Relative Strength Index (RSI)
- TDTH N/A
- PASG 50.18
- Support Level
- TDTH N/A
- PASG $0.40
- Resistance Level
- TDTH N/A
- PASG $0.49
- Average True Range (ATR)
- TDTH 0.00
- PASG 0.05
- MACD
- TDTH 0.00
- PASG 0.00
- Stochastic Oscillator
- TDTH 0.00
- PASG 45.32
About TDTH TRIDENT DIGITAL TECH HOLDINGS LTD SPON ADS EACH REP 8 ORD CL B
Trident Digital Tech Holdings Ltd is principally engaged in the provision of business consulting service and IT customization solutions in the Republic of Singapore. Its revenue is derived from business consulting service, IT customization and selling event tickets.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.